Centrul Medical Monza S.R.L.

Researchers at Centrul Medical Monza S.R.L. are investigating new therapeutic options for ulcerative colitis, aiming to improve disease control and patient quality of life.

• Study of GS-1427 in Participants With Moderately to Severely Active UC
• Evaluation of novel oral and biologic agents targeting intestinal inflammation
• Assessment of patient-reported outcomes and endoscopic healing

The site supports 7 active trials with a team of 9 investigators, contributing to advances in gastrointestinal health from its Bucharest location.

Clinical investigations focus on autoimmune conditions such as systemic lupus erythematosus and plaque psoriasis, testing innovative compounds to reduce disease activity and skin lesions.

• The WILLOW study with enpatoran in SLE and CLE
• Safety and efficacy trial of BI 765250 in moderate to severe plaque psoriasis
• Biomarker-driven analyses of immune modulation

With a multidisciplinary team, the hospital advances immune‑system research while maintaining patient safety as a priority.

The orthopedic wing conducts studies on knee osteoarthritis, seeking treatments that alleviate pain and enhance joint function for older adults.

• Study of efficacy, safety and tolerability of DFV890 in patients with knee osteoarthritis
• Functional outcome assessments using KOOS pain sub‑scale
• Exploration of disease‑modifying agents for cartilage preservation

These trials complement the site’s broader therapeutic portfolio, offering participants access to cutting‑edge musculoskeletal research.

Ongoing research addresses chronic lung conditions including COPD, mild asthma, and non‑cystic fibrosis bronchiectasis, with goals to reduce exacerbations and improve breathing capacity.

• The efficacy and safety of two doses of CHF6001 for the treatment of COPD
• Comparative potency study of salbutamol inhalers in mild asthmatics
• Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients with Pseudomonas Aeruginosa

Leveraging its pulmonary care unit, the facility enrolls patients across disease severity levels, contributing valuable data to respiratory therapeutics.

Dermatology trials target conditions such as plaque psoriasis, evaluating novel agents for skin clearance and long‑term disease management.

• Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus placebo
• Investigation of skin‑specific outcome measures and quality‑of‑life indices
• Exploratory studies on connective tissue biomarkers

The department’s expertise in skin health supports a patient‑centered approach while advancing therapeutic options at the Bucharest site.